Bronchogen
Ala-Glu-Asp-Leu · AEDL · Bronchial bioregulator
Think of it as a maintenance crew for your airways.
Bronchogen is like a mini maintenance crew for your lungs. It's a tiny chain of amino acids designed to slip into your cells and give your bronchial tubes some TLC. Imagine it going to work on your airways, helping to keep the lining of your lungs in good shape and possibly supporting repair processes.
The research behind Bronchogen is mostly focused on how it might help with chronic lung issues. In studies, it's shown some promise in tweaking the way cells in your bronchial tubes behave, potentially leading to healthier lung tissue and less inflammation. But keep in mind, most of this research is still in early stages and hasn't been widely tested in humans yet.
Who it's for
- Smokers looking to support lung health
- People interested in experimental wellness hacks
- Biohackers curious about lung-specific peptides
Probably not for you if…
- Those looking for FDA-approved treatments
- People expecting instant, proven results
- Anyone uncomfortable with experimental therapies
Editorial summary for research context · Not medical advice
Mechanism of Action
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu) designed as a bronchi-targeted bioregulator. Khavinson-group research proposes that short peptides of this class penetrate cell membranes, enter the nucleus, and modulate tissue-specific gene expression in bronchial epithelium. Preclinical work has focused on chronic bronchitis and COPD models. Not FDA-approved. Preclinical and limited clinical data from Khavinson group.
Researched Benefits
Bronchial epithelium gene modulation
Khavinson-lab studies report modulation of gene expression in bronchial cell cultures relevant to epithelial differentiation and mucosal repair.
- [Khavinson & Kuznik 2012]
Preclinical COPD models
Russian-language preclinical studies have examined effects on inflammatory markers and bronchial mucosal structure in rodent COPD models.
- [Chalisova et al. 2014]
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Intranasal / inhaled research protocol
- Dosage
- 100 mcg
- Frequency
- once daily
- Timing
- morning
- Cycle
- 3 weeks
Khavinson-group protocols use short 20-30 day cycles. Intranasal administration most commonly described in literature.
Reported Side Effects
- No significant adverse events reported in published Khavinson-group studies
- Transient local irritation with intranasal delivery
- Long-term human safety data limited
Contraindications
- Pregnancy and lactation (no safety data)
- Active pulmonary malignancy (theoretical concern)
- Individual hypersensitivity to peptide components
Stacking Partners
Peptides commonly paired with Bronchogen in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
6:04Doctor Explains 20 Most Powerful Peptides
This Is Not Covered - Dr. Ashley Froese
472.6K views · 6:04 · 7 months ago
7:43Why I Stopped BPC-157 and TB-500 Peptides - April 26, 2024
Bill Maeda
366.9K views · 7:43 · 2 years ago
5:59TIER LIST PEPTIDE EDITION
Greg Doucette
351.9K views · 5:59 · 1 year ago
10:59Doctor Reviews Peptides - Changing Medicine Forever
This Is Not Covered - Dr. Ashley Froese
179.1K views · 10:59 · 6 months ago
7:15Doctor Explains Your RISK of Cancer From Popular Peptides
This Is Not Covered - Dr. Ashley Froese
173.1K views · 7:15 · 5 months ago
Research Papers
Peptides as regulators of gene expression: a review of Khavinson-group research
Khavinson VKh, Kuznik BI · Advances in Gerontology · 2012